Hodgkin lymphoma, version 2.2012 featured updates to the NCCN guidelines.
J Natl Compr Canc Netw
; 10(5): 589-97, 2012 May.
Article
en En
| MEDLINE
| ID: mdl-22570290
ABSTRACT
The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Hodgkin Lymphoma (HL) include the clinical management of classical HL and lymphocyte-predominant HL (LPHL). Major changes have been incorporated into these guidelines since their inception. In the 2012 NCCN Guidelines for HL, PET scans are not recommended for interim restaging of patients with stage I to II favorable disease. After reevaluating the available evidence on the use of interim PET imaging, the panel recommends the use of diagnostic CT scan of involved sites for interim restaging after completion of chemotherapy for this group of patients. Maintenance rituximab for 2 years is included as an option for patients with stage IB to IIB or stage III to IV LPHL treated with rituximab alone in the first-line setting. Brentuximab vedotin is included as an option for patients with progressive disease or relapsed disease after second-line chemotherapy or high-dose therapy with autologous stem cell rescue.
Buscar en Google
Banco de datos:
MEDLINE
Asunto principal:
Enfermedad de Hodgkin
/
Oncología Médica
/
Antineoplásicos
Tipo de estudio:
Guideline
Límite:
Humans
Idioma:
En
Revista:
J Natl Compr Canc Netw
Asunto de la revista:
NEOPLASIAS
Año:
2012
Tipo del documento:
Article